Risk Factors Update Summary
- Accumulated deficit increased from $327 million to $409 million, raising doubt about continued operations.
- Cash decreased from $95.7 million to $39.7 million, requiring additional funding for operations.
- Employee count increased from 109 to 164 full-time employees, potentially impacting operations.
- Phase 1 and 2 clinical trials expanded to include COVID-19 vaccine candidates, affecting timelines.
- Transition from quadrivalent to trivalent influenza vaccine may impact manufacturing yields and operations.
- Development of tablet vaccine candidates for various diseases faces formulation challenges.
- Risks related to artificial intelligence integration and potential security breaches pose operational threats.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=72444&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.